ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Johnson & Johnson, Geropharm and Hanmi Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Johnson & Johnson×Geropharm×Hanmi Pharmaceutical×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Johnson & JohnsonGeropharmHanmi Pharmaceutical
studies on the registry3,70923191
open to participants now146012
phase 3 studies under way9513
reach primary completion within a year8708
programswith a study of their own in two years56+4 named only112

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJohnson & JohnsonGeropharmHanmi Pharmaceutical
Phase 1

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%
00%

Hanmi Pharmaceutical: 4 of its 12 programs at phase 1

  1. HIP2503phase 1
  2. HM17321phase 1
  3. IL-2 Mutein/Fc Fusion Protein HM16390phase 1
  4. RLD2606phase 1
33%
Phase 2

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%
00%

Hanmi Pharmaceutical: 3 of its 12 programs at phase 2

  1. belvarafenibphase 2
  2. HM15275phase 2
  3. cobimetinibphase 2
25%
Phase 3

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%

Geropharm: 1 of its 1 programs at phase 3

  1. insulin glulisinephase 3
100%

Hanmi Pharmaceutical: 5 of its 12 programs at phase 3

  1. efpeglenatidephase 3
  2. HCP1306phase 3
  3. HCP1803-4phase 3
  4. hip2602phase 3
  5. hpp2602-2phase 3
42%
Approved, new studies

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%
00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Johnson & Johnson26 readouts · 8 phase 3

Johnson & Johnson, Nov ’26: 1 program whose next study reaches primary completion

  1. JNJ-95597528phase 2 · Nov 19 · NCT07230860

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
Geropharm0 readouts · 0 phase 3············
Hanmi Pharmaceutical6 readouts · 3 phase 3··

Hanmi Pharmaceutical, Jan ’27: 1 program whose next study reaches primary completion

  1. HM15275phase 2 · Jan 0 · NCT07205900

Hanmi Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. RLD2606phase 1 · Feb 5 · NCT07939087

Hanmi Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. HM17321phase 1 · Mar 0 · NCT07219589
·····

Hanmi Pharmaceutical, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. hip2602phase 3 · Sep 0 · NCT07899073
  2. hpp2602-2phase 3 · Sep 0 · NCT07899073

Hanmi Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. HCP1803-4phase 3 · Oct 30 · NCT07660796
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Geropharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Hanmi Pharmaceutical

New programs 3

  • RLD2606phase 1 · first study · Nov 10
  • hip2602phase 3 · first study · Oct 20 · Erectile Dysfunction
  • hpp2602-2phase 3 · first study · Oct 20 · Erectile Dysfunction

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionJohnson & JohnsonGeropharmHanmi Pharmaceutical
Neoplasms2 of 3 · compare here–

Hanmi Pharmaceutical in Neoplasms: 2 programs

  1. belvarafenibphase 2
  2. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Neoplasms in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Johnson & Johnson in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. amivantamabphase 3
  2. lazertinibphase 3
  3. hafnium oxidephase 3
  4. anvatabart opadotinphase 2
  5. olomorasibphase 2

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Carcinoma, Non-Small-Cell Lung in search

–

Hanmi Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasms2 of 3 · compare here

Johnson & Johnson in Colorectal Neoplasms: 3 programs

  1. amivantamabphase 3
  2. olomorasibphase 2
  3. JNJ-89402638phase 1

Their studies: Johnson & Johnson’s studies of Colorectal Neoplasms in search

–

Hanmi Pharmaceutical in Colorectal Neoplasms: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Colorectal Neoplasms in search

Diabetes Mellitus, Type 22 of 3 · compare here–

Geropharm in Diabetes Mellitus, Type 2: 1 program

  1. insulin glulisinephase 3

Their studies: Geropharm’s studies of Diabetes Mellitus, Type 2 in search

Hanmi Pharmaceutical in Diabetes Mellitus, Type 2: 2 programs

  1. efpeglenatidephase 3
  2. HM15275phase 2

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Diabetes Mellitus2 of 3 · compare here–

Geropharm in Diabetes Mellitus: 1 program

  1. insulin glulisinephase 3

Their studies: Geropharm’s studies of Diabetes Mellitus in search

Hanmi Pharmaceutical in Diabetes Mellitus: 1 program

  1. efpeglenatidephase 3

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Johnson & Johnson 33 of 56 · Geropharm 1 of 1 · Hanmi Pharmaceutical 5 of 12 programs (24 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Johnson & Johnson: 4).